JUM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fishman, M.
Right arrow Articles by Abramowicz, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fishman, M.
Right arrow Articles by Abramowicz, J.
© 2006 by the American Institute of Ultrasound in Medicine
J Ultrasound Med 25:469-473 • 0278-4297

Changes in the Sonographic Appearance of the Uterus After Discontinuation of Tamoxifen Therapy

Mindy Fishman, MD, Mona Boda, MD, Eyal Sheiner, MD, Jacob Rotmensch, MD and Jacques Abramowicz, MD

Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois USA (M.F., M.B.); Department of Obstetrics and Gynecology, Rush University Medical Center, Chicago, Illinois USA (E.S., J.R., J.A.); and Department of Obstetrics and Gynecology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel (E.S.).

Address correspondence to Jacques S. Abramowicz, MD, Department of Obstetrics and Gynecology, Rush University Medical Center, Chicago, IL 60612 USA. E-mail: jacques_abramowicz{at}rush.edu

Objective. The purpose of this study was to assess the duration of sonographically detected changes in the endometrium of women with a history of tamoxifen use. Methods. Patients with breast cancer who had a history of tamoxifen use and documented pelvic sonographic studies were identified by means of clinic databases in both the Section of Gynecological Oncology and the Section of Obstetrical and Gynecological Ultrasound, University of Chicago, between January 1, 1996, and March 30, 2004. Of the 99 patients who met study criteria, 34 had discontinued tamoxifen use before the sonographic evaluation. Each patient’s age, gravity and parity, weight, ethnicity, duration and dose of drug use, interval from drug discontinuation until sonographic evaluation, and uterine pathologic findings were reviewed. Endometrial thickness as assessed by pelvic sonography was examined in relation to duration of tamoxifen use and time from discontinuation of the drug. Statistical analysis was performed with linear regression and mixed effect linear regression models. Results. Endometrial thickness increased with increasing duration of tamoxifen use at a rate of 0.75 mm/y. The mean endometrial thickness after approximately 5 years of tamoxifen use was 12 mm (range, 6–21 mm). After discontinuation of tamoxifen, endometrial thickness decreased by 1.27 mm/y. Conclusions. Endometrial thickness as measured by pelvic ultrasound examination increases with the duration of tamoxifen use. After discontinuation of the drug, the measured thickness decreases but at a very slow rate.

Key Words: breast cancer • endometrium • sonography • tamoxifen







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Institute of Ultrasound in Medicine.